Reata Pharmaceuticals, Inc’s publication in Journal of Biochemical and Molecular Toxicology
SMC announces that Reata Pharmaceuticals (TX) has published the results of a study using STAM™ model on Journal of Biochemical and Molecular Toxicology.
Title: “Omaveloxolone and TX63682 Are Hepatoprotective in the STAM™ Mouse Model of Nonalcoholic Steatohepatitis”
Omaveloxolone and its analog TX63682, potent activator of Nrf2, demonstrated significant decreased hepatic fat deposition, hepatocellular ballooning, inflammatory cell infiltration, and collagen deposition in the STAM™ model.
Nrf2 is the master transcriptional regulator of antioxidative response.
Therefore, the STAM™ model can be used in the pharmacology studies of the antioxidative related compounds.